What does drug- or procedure-induced sclerosing cholangitis look like on MRCP and how common is it?

Drug-Induced Sclerosing Cholangitis on MRCP

Drug-induced or procedure-related secondary sclerosing cholangitis (SSC) appears on MRCP as localized intrahepatic bile duct strictures with irregularities of the bile duct wall, and occurs in approximately 17-40% of patients with drug-induced liver injury (DILI) who undergo cholangiographic imaging 1, 2.

MRCP Imaging Characteristics

The cholangiographic features of drug-induced SSC differ from primary sclerosing cholangitis in several key ways 1:

• Caustic/drug-induced cholangitis: Localized intrahepatic bile duct strictures with irregularities of bile duct wall (rather than the diffuse multifocal pattern of PSC)
• Distribution pattern: Predominantly segmental distribution (78.6% of cases), with extrahepatic bile duct involvement in approximately 64% 2
• Contrast with PSC: Unlike PSC's characteristic "beaded" appearance with multifocal intrahepatic and extrahepatic strictures, diverticular outpouchings, and "pruned tree" appearance, drug-induced SSC shows more localized changes

Frequency and Clinical Context

The prevalence of drug-related SSC has increased substantially in recent years 2, 3:

• Among DILI patients undergoing MRCP: 17.3% in the most recent cohort (2020-2024) 2, and 40% in an earlier series (25 patients imaged out of 102 DILI cases) 3
• Important caveat: These frequencies reflect selected populations who underwent imaging, not all DILI patients. MRCP is typically performed when there is persistent cholestatic injury or clinical concern for biliary complications

Clinical Predictors Warranting MRCP

You should strongly consider MRCP in DILI patients with 2, 3:

• Peak alkaline phosphatase >550 U/L (identified as independent risk factor; OR 1.002 per unit increase) 2
• Jaundice (present in 70% of drug-induced SSC vs. 23-25% without SSC)
• Cholestatic or mixed pattern of injury (all SSC cases had this pattern)
• Prolonged recovery time (median 114-152 days vs. 61-62 days in DILI without SSC)

Critical Pitfalls

Do not confuse drug-induced SSC with other secondary causes 1:

• Ischemic cholangitis (critical illness): Shows proximal intrahepatic strictures, bile duct necrosis, biliomas, abscesses, and biliary casts
• IgG4-related cholangitis: Multifocal central bile duct strictures with visible bile duct wall thickening and pancreatic abnormalities
• Ascending cholangitis: Multiple intrahepatic strictures with stones and biliary abscesses

The distinction matters because drug-induced SSC carries a worse prognosis than typical DILI, with higher rates of chronic injury (35.7% vs. 10.4%) and potential progression to liver failure requiring transplantation 2, 3, 4.

Diagnostic Approach

When drug-induced SSC is suspected 5, 6:

1. Obtain high-quality MRCP as first-line imaging (sensitivity 86%, specificity 94% for sclerosing cholangitis) 7, 5
2. Exclude other causes: Viral hepatitis, cholelithiasis, alcohol, other medications/supplements, autoimmune overlap syndromes 6
3. Consider liver biopsy if MRCP is equivocal or to rule out alternative diagnoses, though not required when cholangiographic findings are characteristic 7, 5
4. Reserve ERCP for therapeutic intervention or tissue acquisition, not routine diagnosis 7, 5

The recognition of drug-induced SSC is increasingly important given its rising prevalence, particularly with immune checkpoint inhibitors and other newer therapeutic agents 8.